Youlian Zhou

List of Publications by Year
in descending order

35 papers	1,120 citations	516710 16 h-index	580821 25 g-index
37 all docs	37 docs citations	37 times ranked	1875 citing authors

#	Article	IF	Citations
1	Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. MSystems, 2018, 3, .	3.8	204
2	Alteration of the gut microbiota in Chinese population with chronic kidney disease. Scientific Reports, 2017, 7, 2870.	3.3	192
3	Increased Enterococcus faecalis infection is associated with clinically active Crohn disease. Medicine (United States), 2016, 95, e5019.	1.0	83
4	Association of oncogenic bacteria with colorectal cancer in South China. Oncotarget, 2016, 7, 80794-80802.	1.8	70
5	Alterations in the gut microbiota of patients with acquired immune deficiency syndrome. Journal of Cellular and Molecular Medicine, 2018, 22, 2263-2271.	3.6	63
6	Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway. Gut Microbes, 2021, 13, 1-20.	9.8	55
7	Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain. Gastroenterology Research and Practice, 2021, 2021, 1-20.	1.5	51
8	Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Frontiers in Nutrition, 2021, 8, 818902.	3.7	51
9	Linc00483 as ce<scp>RNA</scp> regulates proliferation and apoptosis through activating <scp>MAPK</scp>s in gastric cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 3875-3886.	3.6	49
10	Identification ofClostridium difficileRibotype 027 for the First Time in Mainland China. Infection Control and Hospital Epidemiology, 2014, 35, 95-98.	1.8	37
11	Systematic review and metaâ€analysis of the role of <scp>Faecalibacterium prausnitzii</scp> alteration in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 320-328.	2.8	37
12	NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice. Biochemical and Biophysical Research Communications, 2021, 534, 734-739.	2.1	34
13	Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression. Cellular Physiology and Biochemistry, 2018, 51, 2123-2135.	1.6	32
14	F. prausnitzii and its supernatant increase SCFAs-producing bacteria to restore gut dysbiosis in TNBS-induced colitis. AMB Express, 2021, 11, 33.	3.0	32
15	Sodium Butyrate Ameliorates Gut Microbiota Dysbiosis in Lupus-Like Mice. Frontiers in Nutrition, 2020, 7, 604283.	3.7	26
16	Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?. BioMed Research International, 2019, 2019, 1-11.	1.9	21
17	Gut Microbiota Profile in Adult Patients with Idiopathic Nephrotic Syndrome. BioMed Research International, 2021, 2021, 1-12.	1.9	17
18	Alterations in Gut Microbial Communities Across Anatomical Locations in Inflammatory Bowel Diseases. Frontiers in Nutrition, 2021, 8, 615064.	3.7	14

#	Article	IF	Citations
19	Host Genetic and Environmental Factors Shape the Composition and Function of Gut Microbiota in Populations Living at High Altitude. BioMed Research International, 2020, 2020, 1-10.	1.9	12
20	Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer. Cellular Oncology (Dordrecht), 2020, 43, 409-420.	4.4	12
21	Rapid detection of ermB gene in Clostridium difficile by loop-mediated isothermal amplification. Journal of Medical Microbiology, 2015, 64, 854-861.	1.8	8
22	Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota. BioMed Research International, 2021, 2021, 1-12.	1.9	7
23	Infliximab for the treatment of Crohnâ€™s disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1270-1275.	1.6	6
24	Intestinal mucosal microbiota composition of patients with acquired immune deficiency syndrome in Guangzhou, China. Experimental and Therapeutic Medicine, 2021, 21, 391.	1.8	4
25	Tu1963 Shift From Firmicutes-Enriched to Proteobacteria-Enriched and Specific Clostridials Reduction in Intestinal Microbiota Accociate With Activity of Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S992.	1.3	2
26	Genome insights of Enterococcus raffinosus CX012922, isolated from the feces of a Crohnâ€™s disease patient. Gut Pathogens, 2021, 13, 71.	3.4	1
27	Anti-IL-17 monoclonal antibody for induction of remission in Crohn's disease. The Cochrane Library, 2012, , .	2.8	0
28	Imbalanced Intestinal Microbiota in Treatment-NaÃ¯ve Patients With Inflammatory Bowel Disease by a Metagenomic Approach. American Journal of Gastroenterology, 2014, 109, S493.	0.4	0
29	Tu1787 â€“ Potential Protective Effect of Pd-1 Inhibitor on Tnbsinduced Colitis Via Alteration of Gut Microbiota. Gastroenterology, 2019, 156, S-1123.	1.3	0
30	IDDF2021-ABS-0200â€…Bacillus amyloliquefaciens combined with resistant starch to ameliorate intestinal inflammation. , 2021, , .		0
31	IDDF2021-ABS-0196â€…The effect and immune cell analysis of clostridium butyricum on dextran sulphate sodium induced colitis in mice pretreated with antibiotic cocktail. , 2021, , .		0
32	IDDF2021-ABS-0212â€…Fecal microbiota transplantation ameliorates experimental colitis by regulating autophagy. , 2021, , .		0
33	Sensitive and Rapid Detection of ermB Gene in Clostridium difficile by Loop-Mediated Isothermal Amplification. American Journal of Gastroenterology, 2014, 109, S113.	0.4	0
34	Progressive Decreased Gut Microbial Diversity in Chronic Kidney Disease. American Journal of Gastroenterology, 2014, 109, S204.	0.4	0
35	Risk Factors for Acquisition of C. difficile Toxin-Positive Diarrhea in a Chinese Tertiary Hospital. American Journal of Gastroenterology, 2014, 109, S635.	0.4	0